These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24880619)

  • 61. Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.
    Carubbi F; Cipriani P; Marrelli A; Benedetto P; Ruscitti P; Berardicurti O; Pantano I; Liakouli V; Alvaro S; Alunno A; Manzo A; Ciccia F; Gerli R; Triolo G; Giacomelli R
    Arthritis Res Ther; 2013 Oct; 15(5):R172. PubMed ID: 24286296
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
    Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
    Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combination Therapy of Intravenous Steroids and Orbital Irradiation is More Effective Than Intravenous Steroids Alone in Patients with Graves' Orbitopathy.
    Oeverhaus M; Witteler T; Lax H; Esser J; Führer D; Eckstein A
    Horm Metab Res; 2017 Oct; 49(10):739-747. PubMed ID: 28922676
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy.
    Poonyathalang A; Preechawat P; Charoenkul W; Tangtrakul P
    J Med Assoc Thai; 2005 Mar; 88(3):345-9. PubMed ID: 15962642
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Effect of rituximab in patients with leucine-rich, glioma-inactivated 1 antibody-associated encephalopathy.
    Irani SR; Gelfand JM; Bettcher BM; Singhal NS; Geschwind MD
    JAMA Neurol; 2014 Jul; 71(7):896-900. PubMed ID: 24842754
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Low-dose rituximab combined with short-term glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia.
    Li Z; Mou W; Lu G; Cao J; He X; Pan X; Xu K
    Int J Hematol; 2011 Jan; 93(1):91-8. PubMed ID: 21188563
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.
    Fraticelli P; De Vita S; Franzolini N; Svegliati S; Scott CA; Tonnini C; Spadoni T; Gabrielli B; Pomponio G; Moroncini G; Gabrielli A
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S160-7. PubMed ID: 26339895
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
    Yoo DH; Suh CH; Shim SC; Jeka S; Molina FFC; Hrycaj P; Wiland P; Lee EY; Medina-Rodriguez FG; Shesternya P; Radominski S; Stanislav M; Kovalenko V; Sheen DH; Myasoutova L; Lim MJ; Choe JY; Lee SJ; Lee SY; Kim SH; Park W
    BioDrugs; 2017 Aug; 31(4):357-367. PubMed ID: 28612179
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
    Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
    Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Therapeutic outcomes of high-dose intravenous steroids in the treatment of dysthyroid optic neuropathy.
    Currò N; Covelli D; Vannucchi G; Campi I; Pirola G; Simonetta S; Dazzi D; Guastella C; Pignataro L; Beck-Peccoz P; Ratiglia R; Salvi M
    Thyroid; 2014 May; 24(5):897-905. PubMed ID: 24417307
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Baldovino S; Menegatti E; La Grotta R; Modena V
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Natural history of graves' orbitopathy after treatment.
    Menconi F; Leo M; Sabini E; Mautone T; Nardi M; Sainato A; Sellari-Franceschini S; Vitti P; Marcocci C; Marinò M
    Endocrine; 2017 Aug; 57(2):226-233. PubMed ID: 27709471
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Treatment of severe uveitis associated with juvenile idiopathic arthritis with anti-CD20 monoclonal antibody (rituximab).
    Heiligenhaus A; Miserocchi E; Heinz C; Gerloni V; Kotaniemi K
    Rheumatology (Oxford); 2011 Aug; 50(8):1390-4. PubMed ID: 21378109
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
    Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
    Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
    Unger L; Kampf S; Lüthke K; Aringer M
    Rheumatology (Oxford); 2014 Sep; 53(9):1630-8. PubMed ID: 24706995
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab].
    Hayashi R; Tahara M; Oeda T; Konishi T; Sawada H
    Rinsho Shinkeigaku; 2015; 55(4):227-32. PubMed ID: 25904250
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
    Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
    Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report.
    Foster CS; Chang PY; Ahmed AR
    Ophthalmology; 2010 May; 117(5):861-9. PubMed ID: 20045562
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Effect of a single-cycle alternative dosing regimen for rituximab for recalcitrant pemphigus: a case series of 9 patients.
    Matsukura S; Knowles SR; Walsh S; Shear NH
    Arch Dermatol; 2012 Jun; 148(6):734-9. PubMed ID: 22351790
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prevention of Orbitopathy by Oral or Intravenous Steroid Prophylaxis in Short Duration Graves' Disease Patients Undergoing Radioiodine Ablation: A Prospective Randomized Control Trial Study.
    Vannucchi G; Covelli D; Campi I; Currò N; Dazzi D; Rodari M; Pepe G; Chiti A; Guastella C; Lazzaroni E; Salvi M
    Thyroid; 2019 Dec; 29(12):1828-1833. PubMed ID: 31860407
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.